[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acoustic-neuroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acoustic-neuroma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100630882","early-phase-1-pilot-study-evaluating-panitumumab-irdye800-as-an-optical-imaging-agent-to-detect-intracranial-lesions-during-neurosurgical-procedures-100630882",false,"NCT07493447","Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures","Inclusion Criteria:\n\n* Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and\u002For radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection.\n* Subject age ≥ 18 years.\n* Adequate hematologic and end-organ function appropriate for surgery and panitumumab infusion as determined by routine preoperative evaluation or designee prior to infusion. If liver function, renal function, and hematologic laboratory test results are acceptable for elective surgery and panitumumab infusion, the patient is considered eligible for the study. Laboratory results will need to be obtained within 30 days prior to initiation of study treatment include:\n\n  1. Chemistry Panel - Potassium, BUN (or urea), and Creatinine\n  2. CBC with differential - WBC, including ANC, hemoglobin, hematocrit, and platelet count\n  3. Magnesium and Phosphorus\n* Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration.\n* Ability to understand and willingness to sign a written informed document or written informed consent via a surrogate consent rider from the patients' healthcare decision maker.\n\nExclusion Criteria:\n\n* Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment.\n* History of infusion reactions to any monoclonal antibody therapies.\n* Women who are currently pregnant or breastfeeding.\n* Participants presenting with a baseline QTcF interval \\> than 480 milliseconds.\n* Magnesium or phosphorus lower than normal institutional values, and subject is symptomatic.\n* Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n* Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n* Patients with severe renal disease or anuria","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.",[25,26,27,28,29],"Meningioma","Glioblastoma","Acoustic Neuroma","Brain Cancer","Pituitary Adenoma",[31,32,33,26,25,29,27,34,35],"Cancer","Malignant","Benign","Brain Masses","Intracranial Lesion","RECRUITING","2026-06-26",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":19},"2026-07",{"date":44,"type":19},"2031-06",{"name":46,"class":47},"Eben Rosenthal","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":15,"minAge":16,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":20,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100524728","evolution-of-vestibular-function-after-treatment-of-a-vestibular-schwannoma-by-gamma-knife-radio-surgery-100524728","NCT06112509","Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery","Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife","EVERS","Inclusion Criteria :\n\n* Men and women aged 18 to 90 included\n* Subject who benefited from gamma-knife radiosurgery as part of the treatment of vestibular schwannoma\n* Non-opposition of the subject to participate in the study\n* Affiliation to a French social security scheme or beneficiary of such a scheme\n\nExclusion Criteria :\n\n* Subject with another vestibular pathology\n* Subject who did not benefit from a vestibular assessment before treatment with gamma-knife radiosurgery\n* Legal incapacity or limited legal capacity\n* Subject unlikely to cooperate in the study and\u002For weak cooperation anticipated by the investigator\n* Subject without health insurance\n* Subject being in the period of exclusion from another study or provided for by the \"national volunteer file\".",true,"90 Years",{"count":60,"type":19},20,[62],"NA","The purpose of this study is to evaluate the vestibular effects of gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma.",[65,66,27],"Vestibular Schwannoma","Neurinoma, Acoustic",[68,69,70,71,72,73],"vestibular","schwannoma","radiosurgery","gamma-knife","neurinoma","acoustic","2024-09-05",{"date":76,"type":40},"2024-09-19",{"date":78,"type":40},"2024-02-20",{"date":80,"type":19},"2024-11-01",{"name":82,"class":47},"Centre Hospitalier Universitaire de Besancon"]